



Press Release

December 13 2005

3i backs Ulthera in bringing therapeutic ultrasound product to cosmetics market

Phoenix, AZ - December 13 2005, Ulthera, a therapeutic ultrasound medical device company targeting the cosmetics market, today announced that it has raised \$5.5m in Series A funding from world leading venture capital firm, 3i.

3i Investors Allan Ferguson and Paul Badawi join Ulthera co-founder, CEO and Chairman, Michael Slayton on the board.

“What really differentiates Ulthera is the integration of imaging and therapy in a single device to perform non-invasive facelifts and wrinkle treatments. Physicians will be able to deposit energy precisely where it’s needed and avoid creating tissue effects anywhere else. This will increase cosmetic efficacy while also providing an improved safety profile,” stated Allan Ferguson, Head of 3i US Venture Capital. “These first to market products address a huge unmet need in the aesthetic, plastic surgery and dermatology professional markets”.

The company has developed a micro-ablation device to safely penetrate and ablate the various layers of skin tissue, non-invasively. Products rely on high frequency ultrasound technology to visualize target tissue layers and create precise lesions in these sub-epidermal layers of tissue, while sparing the outer epidermal layer of skin.

“Our relationship with 3i and their extensive international network will help the Company in several ways, particularly acceleration of commercial activities following product launch, scheduled for 2006”, stated Ulthera President and co-founder, Brian O’Connor.

Ulthera's therapeutic ultrasound platform is ground-breaking for cosmetic dermatology today. "The cosmetics market has been expanding very rapidly over the last few years and we believe we have identified the right team to lead the next phase of innovation in this space. Ulthera's founders have a long history of working together and developing both diagnostic and therapeutic ultrasound technologies. We expect that patients will be very receptive to their latest non-invasive microablation technology. Thought leading dermatologists and plastic surgeons are very much in support of the company and team," added Paul Badawi, 3i director and Ulthera board member.

Ulthera is currently conducting clinical trials at leading U.S. medical centers and expects to receive FDA 510(k) clearance to market products during 2006.

-Ends-

For further information, contact:
Brian O'Connor, President, Ulthera
boconnor@ulthera.com

Tel: +1 480 649 4399

Rachel Richards, 3i press office
rachel.richards@3i.com

Tel: +1 781 839 2627

NOTES TO EDITORS

About Ulthera

Ulthera, Inc. develops novel therapeutic medical devices for the expanding aesthetic, cosmetic surgery and dermatology markets. This market is defined by consumers wishing to improve their appearance by correcting congenital or acquired benign skin pathologies or to reverse the natural effects of aging. Ulthera's initial indications for use address the non-invasive face lift and facial rejuvenation market segment, which will exceed \$4 billion worldwide in 2010.

<http://www.ulthera.com>

About 3i

3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital and Venture Capital and invest across Europe, in the United States and in Asia Pacific. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business.

During 2005, 3i's VC healthcare team has invested in Ulthera, Endosense, Triage Wireless and elbion. 2005 has also been a strong year for successful exits for 3i, with some of the businesses sold to other firms including Arakis, NeoPharma, PharMetrics, SpineNext and Arexis and IPOs for ProStrakan, Arpida, Paion, Phoqus and Ardana.

<http://www.3i.com/>